Breaking News: The US FDA has approved Janssen Pharmaceutical’s INVEGA HAFYERA (6-month paliperidone palmitate), a long-acting, atypical antipsychotic for adults with schizophrenia.
Breaking News: The US FDA has approved Janssen Pharmaceutical’s INVEGA HAFYERA (6-month paliperidone palmitate), a long-acting, atypical antipsychotic for adults with schizophrenia.
Breaking News: The US FDA has...